Home / Resource Library / High risk of infection in ‘real-world’ patients receiving ibrutinib, idelalisib or venetoclax for mature B-cell leukaemia/lymphoma
High risk of infection in ‘real-world’ patients receiving ibrutinib, idelalisib or venetoclax for mature B-cell leukaemia/lymphoma